Physician

Joseph M. Sennabaum, M.D.

According to 2025 Medicare claims, Joseph Sennabaum, M.D. (NPI: 1841261906) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Pasco, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34667-6594.

Sennabaum's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 476 traditional Medicare patients, billed 183,287 HCPCS/CPT codes, and received $3,304,766 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,468 prescription claims across 248 beneficiaries totaling $4,821,620 in drug costs, led by Revlimid (Lenalidomide). 2021 DME data shows 12 claims. Open Payments data shows 19 records totaling $430. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $795,824 to $4,821,620. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	787	241,434	$2,396,825
2016	832	291,296	$3,195,505
2017	817	258,057	$3,478,801
2018	753	260,910	$3,165,457
2019	736	288,395	$3,174,074
2020	665	301,923	$3,415,619
2021	585	198,173	$2,599,160
2022	538	199,674	$2,605,052
2023	560	179,588	$2,579,664
2024	476	183,287	$3,304,766

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	173	1,175	$795,824
2016	202	1,379	$1,415,289
2017	219	1,587	$1,710,704
2018	211	1,342	$2,030,257
2019	203	1,317	$3,454,035
2020	214	1,343	$4,548,679
2021	242	1,522	$6,147,176
2022	254	1,389	$5,355,606
2023	245	1,417	$4,559,785
2024	248	1,468	$4,821,620

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	38	$16,803
2016	N/R	98	$5,449
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	12	$1,699
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	172	565	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	180	428	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	161	351	$13
36415	Insertion of needle into vein for collection of blood sample	354	1,071	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	365	1,405	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	114	3,157	$2,147,925
Ibrance	Palbociclib	48	1,344	$754,438
Pomalyst	Pomalidomide	26	728	$488,337
Verzenio	Abemaciclib	19	532	$266,082
Xalkori	Crizotinib	12	360	$258,516

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	19	$430	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Joseph M. Sennabaum, M.D.?

Tedicare shows public-source Medicare data for Joseph M. Sennabaum, M.D. (NPI 1841261906), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joseph M. Sennabaum, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Joseph M. Sennabaum, M.D.?

Joseph M. Sennabaum, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Joseph M. Sennabaum, M.D. have Open Payments data?

Joseph M. Sennabaum, M.D. has 19 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.